Amgen Inc. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax
Amgen Inc. (AMGN) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax of $19.00 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax · last filed 2015-11-02
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2015-09-30 was $19.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2015-06-30 was $226.00M, a 370.83% increase year-over-year.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2015-03-31 was -$114.00M, a 914.29% decline year-over-year.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2014-12-31 was -$90.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2014 was -$203.00M, a 338.82% decline from fiscal 2013.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2013 was $85.00M, a 36.57% decline from fiscal 2012.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2012 was $134.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2011 was -$112.00M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 12 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2015-09-30 | $19.00M 10-Q · filed 2015-11-02 | $245.00M derived: sum of 2 quarters · filed 2015-11-02 | $131.00M derived: sum of 3 quarters · filed 2015-11-02 | $41.00M derived: sum of 4 quarters · filed 2015-11-02 | |
| 2015-06-30 | $226.00M 10-Q · filed 2015-11-02 | $112.00M derived: sum of 2 quarters · filed 2015-11-02 | $22.00M derived: sum of 3 quarters · filed 2015-11-02 | -$153.00M derived: sum of 4 quarters · filed 2015-11-02 | |
| 2015-03-31 | -$114.00M 10-Q · filed 2015-11-02 | -$204.00M derived: sum of 2 quarters · filed 2015-11-02 | -$379.00M derived: sum of 3 quarters · filed 2015-11-02 | -$331.00M derived: sum of 4 quarters · filed 2015-11-02 | |
| 2014-12-31 | -$90.00M derived: 10-K 12 month − 3 quarters · filed 2015-02-19 | -$265.00M derived: sum of 2 quarters · filed 2015-02-19 | -$217.00M derived: sum of 3 quarters · filed 2015-02-19 | -$203.00M 10-K · filed 2015-02-19 | |
| 2014-09-30 | -$175.00M 10-Q · filed 2014-10-29 | -$127.00M derived: sum of 2 quarters · filed 2014-10-29 | -$113.00M derived: sum of 3 quarters · filed 2014-10-29 | ||
| 2014-06-30 | $48.00M 10-Q · filed 2014-10-29 | $62.00M derived: sum of 2 quarters · filed 2014-10-29 | |||
| 2014-03-31 | $14.00M 10-Q · filed 2014-10-29 | ||||
| 2013-12-31 | $85.00M 10-K · filed 2015-02-19 | ||||
| 2013-09-30 | $159.00M 10-Q · filed 2013-10-29 | $177.00M derived: sum of 2 quarters · filed 2013-10-29 | $33.00M derived: sum of 3 quarters · filed 2013-10-29 | ||
| 2013-06-30 | $18.00M 10-Q · filed 2013-10-29 | -$126.00M derived: sum of 2 quarters · filed 2013-10-29 | |||
| 2013-03-31 | -$144.00M 10-Q · filed 2013-10-29 | ||||
| 2012-12-31 | $134.00M 10-K · filed 2015-02-19 | -$134.00M 10-K · filed 2014-02-24 | |||
| 2011-12-31 | -$112.00M 10-K · filed 2014-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |